Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29597336 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HPGDTSHRHSD17B10ABL1 | |
| SCHEMBL26712136 | 0.88 | ALDH1A1 (0.42) | ALDH1A1HPGDTSHRHSD17B10ABL1 | |
| SCHEMBL363322 | 0.86 | CA1 (0.43) | ALDH1A1HPGDTSHRHSD17B10ABL1 | |
| SCHEMBL9110483 | 0.84 | CA1 (0.47) | ALDH1A1HPGDTSHRHSD17B10ABL1 | |
| SCHEMBL473842 | 0.82 | TSHR (0.47) | ALDH1A1HPGDTSHRHSD17B10L3MBTL1 | |
| SCHEMBL29952155 | 0.82 | MAP2K1 (0.40) | ALDH1A1L3MBTL1CA1CA2GAA | |
| SCHEMBL2825641 | 0.81 | CA12 (0.62) | ALDH1A1HPGDTSHRHSD17B10CA12 | |
| SCHEMBL15516681 | 0.81 | CA2 (0.41) | ALDH1A1HPGDTSHRHSD17B10ABL1 | |
| SCHEMBL29952002 | 0.81 | CA12 (0.62) | ALDH1A1HPGDTSHRHSD17B10CA12 | |
| SCHEMBL4847318 | 0.80 | CES2 (0.39) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4480477-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | Kanaph Therapeutics Inc. (KR) | 2024-12-25 | — | — | EP | disclosed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4428134-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024133560-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | DARK BLUE THERAPEUTICS LTD (GB) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389747-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2024-06-26 | — | — | EP | disclosed |
| US-20240166624-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | disclosed |
| CN-112480116-B | PKB inhibitors | 南京正大天晴制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024044183-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-2307422-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110077262-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | MSD K.K. (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-2222638-A2 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010012740-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010002010-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-01-07 | — | — | WO | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| WO-2009067600-A2 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067600-A2 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | HAVCR2, HDGF, SLC10A1 | ALDH1A1 3610/4885HPGD 647/4885TSHR 3933/4885 |
| US-20240166624-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | ALDH1A1 1283/4885HPGD 371/4885TSHR 173/4885 |
| US-20240140922-A1 | FUSED HETEROBICYCLIC ANTIVIRAL AGENTS | HAVCR2, HDGF, SLC10A1 | ALDH1A1 3377/4885HPGD 582/4885TSHR 4065/4885 |
| US-20110077262-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | CNKSR1, CBR1, CBR3 | ALDH1A1 220/4885HPGD 2800/4885TSHR 932/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | ALDH1A1 1707/4885HPGD 1644/4885TSHR 3056/4885 |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | ALDH1A1 150/4885HPGD 806/4885TSHR 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.